Table 1.
Subject demographics
| Case Demographics (n = 192) | |||||
| ADNI | ADNI Prodromal | ADNI Mild- | Other Cohort | All Cases | |
| Preclinical AD | AD (MCI) | moderate AD | MCI/AD | (n = 192) | |
| (n = 64) | (n = 71) | (n = 33) | (n = 24) | ||
| Age Avg. (Std. Dev.) | 76 (±6) | 73 (±8) | 74 (±7) | 75 (±9) | 75 (±7) |
| Sex (Male %) | 59.4% | 54.9% | 30.3% | 58.3% | 52.6% |
| Ethnicity | |||||
| -Asian (%) | 1.6% | 4.2% | 0.0% | NA | 2.5% |
| -Black (%) | 7.8% | 1.4% | 0.0% | NA | 3.8% |
| -Hispanic (%) | 1.6% | 2.8% | 0.0% | NA | 1.9% |
| -White (%) | 89.1% | 91.5% | 100.0% | 100.0% | 91.8% |
| ApoE Proteotype | |||||
| -E2/E3 (%) | 6.3% | 1.4% | 0.0% | NA | 3.1% |
| -E2/E4 (%) | 3.1% | 0.0% | 0.0% | NA | 1.3% |
| -E3/E3 (%) | 54.7% | 29.6% | 29.2% | NA | 39.6% |
| -E3/E4 (%) | 29.7% | 53.5% | 41.7% | NA | 42.1% |
| -E4/E4 (%) | 6.3% | 15.5% | 29.2% | NA | 13.8% |
| MMSE Avg. (Std. Dev.) | 29 (±1) | 27 (±2) | 24 (±2) | NA | 27 (±2) |
| CSF Aβ42 Avg. (Std. Dev.) | 182 (±56) | 135 (±32) | 141 (±45) | NA | 152 (±48) |
| CSF Tau Avg. (Std. Dev.) | 78 (±35) | 119 (±53) | 108 (±42) | NA | 104 (±49) |
| CSF pTau Avg. (Std. Dev.) | 31 (±17) | 44 (±15) | 38 (±12) | NA | 39 (±17) |
| Control Demographics (n = 136) | |||||
| Cognitively | Non- | Neurodegenerative | All Controls | ||
| Normal | neurodegenerative | Control –PD | (n = 136) | ||
| Control | Control - Breast | (n = 18) | |||
| (n = 106) | Cancer | (n = 12) | |||
| Age Avg. (Std. Dev.) | 56 (±12) | 47 (±6) | 60 (±9) | 55 (±11) | |
| Sex (Male %) | 50.9% | 0.0% | 33.0% | 42.6% | |
| Ethnicity (White) | 100.0% | 100.0% | 100.0% | 100.0% | |
The number of individuals (n), age, gender, and race are listed for each case and control group. For ADNI samples, ApoE proteotype, MMSE, and CSF Aβ42, tau, and pTau are included as additional data.